156 related articles for article (PubMed ID: 11751474)
61. Chromosome 18 deletions are common events in classical midgut carcinoid tumors.
Löllgen RM; Hessman O; Szabo E; Westin G; Akerström G
Int J Cancer; 2001 Jun; 92(6):812-5. PubMed ID: 11351300
[TBL] [Abstract][Full Text] [Related]
62. [Detection of alterations of the DPC4 gene in paraffin-embedded tissues of pancreatic carcinomas].
Gu L; Cui Q; Chen J; Li L; Liu T
Zhonghua Bing Li Xue Za Zhi; 2000 Aug; 29(4):256-8. PubMed ID: 11866919
[TBL] [Abstract][Full Text] [Related]
63. Genetics of adenocarcinomas of the small intestine: frequent deletions at chromosome 18q and mutations of the SMAD4 gene.
Bläker H; von Herbay A; Penzel R; Gross S; Otto HF
Oncogene; 2002 Jan; 21(1):158-64. PubMed ID: 11791187
[TBL] [Abstract][Full Text] [Related]
64. Genomic sequencing of DPC4 in the analysis of familial pancreatic carcinoma.
Moskaluk CA; Hruban RH; Schutte M; Lietman AS; Smyrk T; Fusaro L; Fusaro R; Lynch J; Yeo CJ; Jackson CE; Lynch HT; Kern SE
Diagn Mol Pathol; 1997 Apr; 6(2):85-90. PubMed ID: 9098646
[TBL] [Abstract][Full Text] [Related]
65. Identification of an agent selectively targeting DPC4 (deleted in pancreatic cancer locus 4)-deficient pancreatic cancer cells.
Wang H; Han H; Von Hoff DD
Cancer Res; 2006 Oct; 66(19):9722-30. PubMed ID: 17018631
[TBL] [Abstract][Full Text] [Related]
66. Pancreatic carcinoma in carriers of a specific 19 base pair deletion of CDKN2A/p16 (p16-leiden).
de vos tot Nederveen Cappel WH; Offerhaus GJ; van Puijenbroek M; Caspers E; Gruis NA; De Snoo FA; Lamers CB; Griffioen G; Bergman W; Vasen HF; Morreau H
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3598-605. PubMed ID: 14506146
[TBL] [Abstract][Full Text] [Related]
67. ACVR1B (ALK4, activin receptor type 1B) gene mutations in pancreatic carcinoma.
Su GH; Bansal R; Murphy KM; Montgomery E; Yeo CJ; Hruban RH; Kern SE
Proc Natl Acad Sci U S A; 2001 Mar; 98(6):3254-7. PubMed ID: 11248065
[TBL] [Abstract][Full Text] [Related]
68. Differential roles of alterations of p53, p16, and SMAD4 expression in the progression of intraductal papillary-mucinous tumors of the pancreas.
Sasaki S; Yamamoto H; Kaneto H; Ozeki I; Adachi Y; Takagi H; Matsumoto T; Itoh H; Nagakawa T; Miyakawa H; Muraoka S; Fujinaga A; Suga T; Satoh M; Itoh F; Endo T; Imai K
Oncol Rep; 2003; 10(1):21-5. PubMed ID: 12469138
[TBL] [Abstract][Full Text] [Related]
69. DPC-4 (Smad-4) and K-ras gene mutations in biliary tract epithelium in children with anomalous pancreaticobiliary ductal union.
Shimotake T; Aoi S; Tomiyama H; Iwai N
J Pediatr Surg; 2003 May; 38(5):694-7. PubMed ID: 12720172
[TBL] [Abstract][Full Text] [Related]
70. Correspondence re: Seki et al., Diagnosis of pancreatic adenocarcinoma by detection of human telomerase reverse transcriptase messenger RNA in pancreatic juice with sample qualification. Clin. Cancer Res., 7: 1976-1981, 2001.
Hindle KS; Kirkpatrick K; Mokbel K
Clin Cancer Res; 2002 Feb; 8(2):628-9. PubMed ID: 11839686
[No Abstract] [Full Text] [Related]
71. Pancreatic carcinoma cell lines with SMAD4 inactivation show distinct expression responses to TGFB1.
Jonson T; Heidenblad M; Håkansson P; Gorunova L; Johansson B; Fioretos T; Höglund M
Genes Chromosomes Cancer; 2003 Apr; 36(4):340-52. PubMed ID: 12619158
[TBL] [Abstract][Full Text] [Related]
72. The utility of SMAD4 as a diagnostic immunohistochemical marker for pancreatic adenocarcinoma, and its expression in other solid tumors.
Ali S; Cohen C; Little JV; Sequeira JH; Mosunjac MB; Siddiqui MT
Diagn Cytopathol; 2007 Oct; 35(10):644-8. PubMed ID: 17854080
[TBL] [Abstract][Full Text] [Related]
73. Transforming growth factor-beta responsiveness in DPC4/SMAD4-null cancer cells.
Dai JL; Schutte M; Bansal RK; Wilentz RE; Sugar AY; Kern SE
Mol Carcinog; 1999 Sep; 26(1):37-43. PubMed ID: 10487520
[TBL] [Abstract][Full Text] [Related]
74. Role of Smad4 (DPC4) inactivation in human cancer.
Miyaki M; Kuroki T
Biochem Biophys Res Commun; 2003 Jul; 306(4):799-804. PubMed ID: 12821112
[TBL] [Abstract][Full Text] [Related]
75. Assessment of K-ras, Smad4 and p53 gene alterations in colorectal metastases and their role in the metastatic process.
Losi L; Luppi G; Benhattar J
Oncol Rep; 2004 Dec; 12(6):1221-5. PubMed ID: 15547741
[TBL] [Abstract][Full Text] [Related]
76. MUC1 overexpression is the most reliable marker of invasive carcinoma in intraductal papillary-mucinous tumor (IPMT).
Ueda M; Miura Y; Kunihiro O; Ishikawa T; Ichikawa Y; Endo I; Sekido H; Togo S; Shimada H
Hepatogastroenterology; 2005; 52(62):398-403. PubMed ID: 15816444
[TBL] [Abstract][Full Text] [Related]
77. SCF(beta-TrCP1) controls Smad4 protein stability in pancreatic cancer cells.
Wan M; Huang J; Jhala NC; Tytler EM; Yang L; Vickers SM; Tang Y; Lu C; Wang N; Cao X
Am J Pathol; 2005 May; 166(5):1379-92. PubMed ID: 15855639
[TBL] [Abstract][Full Text] [Related]
78. DPC4/Smad4: no mutations, rare allelic imbalances, and retained protein expression in pancreatic endocrine tumors.
Perren A; Saremaslani P; Schmid S; Bonvin C; Locher T; Roth J; Heitz PU; Komminoth P
Diagn Mol Pathol; 2003 Dec; 12(4):181-6. PubMed ID: 14639103
[TBL] [Abstract][Full Text] [Related]
79. MAD-related genes on 18q21.1, Smad2 and Smad4, are altered infrequently in esophageal squamous cell carcinoma.
Maesawa C; Tamura G; Nishizuka S; Iwaya T; Ogasawara S; Ishida K; Sakata K; Sato N; Ikeda K; Kimura Y; Saito K; Satodate R
Jpn J Cancer Res; 1997 Apr; 88(4):340-3. PubMed ID: 9197523
[TBL] [Abstract][Full Text] [Related]
80. Mutations in the SMAD4/DPC4 gene in juvenile polyposis.
Howe JR; Roth S; Ringold JC; Summers RW; Järvinen HJ; Sistonen P; Tomlinson IP; Houlston RS; Bevan S; Mitros FA; Stone EM; Aaltonen LA
Science; 1998 May; 280(5366):1086-8. PubMed ID: 9582123
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
